The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-10

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers and Imaging Markers for ICH

NCT06462274

Intracerebral Hemorrhage

RECRUITING

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NCT02014896

Ischemic Stroke Atrial Fibrillation Transient Ischemic Attacks +4 more

COMPLETED

Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke

NCT06729385

Stroke

COMPLETED

StrokeCog-BBB to Study Cognitive Outcomes Following Stroke

NCT06116630

Stroke

RECRUITING

Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke

NCT06170086

Stroke, Acute

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB injury often occurs in the early stage of ischemic stroke, leading brain tissue edema or even hemorrhagic transformation with the development of ischemic injury. The biomarker of BBB damage, such as the level of serum occludin, can reflect the extent of BBB injury. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

the level of biomarker in bood

Elisa is used to test the level of biomarker in blood.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Enrolled patients aged 18-80years.
2. Acute ischemic stroke
3. Informed consent obtained.

Exclusion Criteria

1. Tumor stroke or hemorrhagic stroke or hemorrhagic cerebral infarction on admission.
2. Stroke or serious head trauma within the previous 3 months
3. inflammatory or infectious diseases, cancer, coagulation disturbance disease and severe renal and liver failure
4. blood sample occurred hemolysis or cloudy.
5. Incomplete clinical data
6. Platelet count of less than 100,000 per cubic millimeter
7. Received oral anticoagulation therapy preceding the onset of stroke and INR greater than 1.7 or prothrombin times greater than 15 seconds
8. Pregnant or breast-feeding women
9. Patients being enrolled or having been enrolled in other clinical trial -

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No